Pharmacia, Merck Explain FDA Cmte. Review Of COX-2 Safety To Investors
Executive Summary
Pharmacia expects both its COX-2 inhibitor Celebrex and Merck's competing Vioxx to receive comparable gastrointestinal safety labeling following a Feb. 7-8 FDA advisory committee meeting.
You may also be interested in...
COX-2 Class Labeling From Vioxx/Celebrex Data Proposed By FDA Consultant
Class labeling for COX-2 inhibitors incorporating data from Pharmacia's Celebrex and Merck's Vioxx large-scale safety studies may be useful in explaining differential safety results in gastrointestinal and cardiovascular adverse events, a consultant to FDA's Arthritis Advisory Committee suggested Feb. 8.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011